RANDOMIZED CONTROLLED DOUBLE BLIND CLINICAL TRIALS VERSUS OPEN TRIALS

被引:0
|
作者
Siegert, J. [1 ]
Hillger, C. [1 ,2 ]
Kirch, W. [1 ]
Schindler, C. [1 ]
机构
[1] Tech Univ Dresden, Inst Klin Pharmakol, D-01307 Dresden, Germany
[2] Forsch Verbund Publ Hlth Sachsen, D-01307 Dresden, Germany
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:40 / 40
页数:1
相关论文
共 50 条
  • [31] Patient adherence: A blind spot of randomized controlled trials?
    Davis, M
    Rathouz, P
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (07) : 252A - 252A
  • [32] PLACEBO-CONTROLLED, DOUBLE-BLIND TRIALS
    KENT, GG
    LANCET, 1980, 1 (8182): : 1363 - 1364
  • [34] STATISTICS IN QUESTION - ASSESSING CLINICAL-TRIALS - DOUBLE-BLIND TRIALS
    GORE, SM
    BRITISH MEDICAL JOURNAL, 1981, 283 (6284): : 122 - 124
  • [35] The blind leading the blind: Use and misuse of blinding in randomized controlled trials
    Miller, Larry E.
    Stewart, Morgan E.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (02) : 240 - 243
  • [36] Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity
    Greenway, F
    Heber, D
    Raum, W
    Morales, S
    OBESITY RESEARCH, 1999, 7 (04): : 370 - 378
  • [37] Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline A Pooled Analysis
    Tonstad, Serena
    Davies, Simon
    Flammer, Martina
    Russ, Cristina
    Hughes, John
    DRUG SAFETY, 2010, 33 (04) : 289 - 301
  • [38] Up a blind alley without double-blind controlled trials
    Niggemann, B.
    Beyer, K.
    ALLERGY, 2007, 62 (01) : 83 - 83
  • [39] THE SAFETY AND TOLERABILITY OF LACOSAMIDE IN RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II/III CLINICAL TRIALS
    Gil-Nagel, A.
    Biton, V.
    Fountain, N.
    Rosenow, F.
    Hebert, D.
    Doty, P.
    EPILEPSIA, 2009, 50 : 110 - 110
  • [40] Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of VareniclineA Pooled Analysis
    Serena Tonstad
    Simon Davies
    Martina Flammer
    Cristina Russ
    John Hughes
    Drug Safety, 2010, 33 : 289 - 301